Nandrolone Bloodwork: The Complete Monitoring Protocol

Nandrolone is a 19-nor derivative of testosterone, meaning it lacks the 19th carbon atom that distinguishes testosterone from other steroids. This structural change has profound effects on its pharmacology and, consequently, on what you need to monitor.

Unlike testosterone, nandrolone has a very low androgenic ratio — approximately 37:37:1 relative to testosterone. This means it binds to the androgen receptor with moderate affinity but produces strong anabolic effects relative to its androgenic activity. The result is excellent muscle growth with relatively low androgenic side effects like hair loss and acne.

The key distinction for monitoring purposes is that nandrolone has significant progestin activity. It binds to the progesterone receptor, which is the mechanism behind its most distinctive side effects: prolactin elevation, libido suppression, and the phenomenon known as "Deca dick." Progestin activity also contributes to nandrolone's immunosuppressive effects and its impact on mood.

Nandrolone's long ester chain (Decanoate for Deca, Phenylpropionate for NPP) means it has a correspondingly long half-life. Decanoate has a half-life of approximately 15 days, which means it takes 75+ days to reach steady state and over 100 days to fully clear from your system. This profoundly affects recovery timelines, as we will discuss in the HPTA section.

Prolactin is the single most under-monitored marker in nandrolone users. In our database, fewer than one in five nandrolone users have prolactin measured at any point during their cycle. This is a significant gap because nandrolone is the most common cause of elevated prolactin among AAS users.

The mechanism is straightforward: nandrolone's progestin activity at the progesterone receptor stimulates prolactin release from the anterior pituitary. This is the same pathway that causes prolactin elevation in pregnancy — progestin dominance signals the pituitary to increase prolactin production.

The threshold for action on prolactin depends on symptoms. Some athletes experience significant libido suppression at prolactin levels as low as 20 ng/mL, while others tolerate levels up to 40 ng/mL without noticeable effects. Current research suggests that prolactin above 30 ng/mL in a male warrants intervention, regardless of symptoms.

It is also important to distinguish between nandrolone's prolactin elevation and the prolactin elevation seen with other causes. Nandrolone-driven prolactin is usually mild to moderate (15-40 ng/mL) compared to the extreme elevations seen with pituitary tumors or antipsychotic medications. However, even mild prolactin elevation has significant effects on sexual function and mood because of nandrolone's concurrent progestin activity — the two mechanisms compound each other at the receptor level.

Nandrolone's impact on lipids is often described as "moderate" — which is true compared to orals or trenbolone, but misleading if interpreted as "insignificant." The evidence shows that nandrolone suppresses HDL by approximately 20-35% at typical doses (300-600 mg/week) and raises ApoB and LDL particle number even as total LDL may appear stable.

The key takeaway: nandrolone's lipid impact is real but manageable. The HDL suppression is not as dramatic as with trenbolone or oral compounds, but it is persistent due to nandrolone's long half-life. Unlike testosterone, where lipids recover within weeks of cessation, nandrolone's lipid effects can persist for 2-3 months after the last injection.

The 19-nor structure does more than just enable progestin activity — it fundamentally alters how the compound interacts with lipid metabolism enzymes. Understanding this mechanism explains why nandrolone's lipid effects differ from both testosterone and other AAS compounds, and why standard lipid panels can miss the full picture.

The key player is hepatic lipase, an enzyme that helps clear HDL particles and remodel LDL. Nandrolone, like all androgens, increases hepatic lipase activity. But unlike testosterone, nandrolone's 19-nor structure appears to have a disproportionately strong effect on this enzyme relative to its androgenic potency. This means nandrolone can suppress HDL more than you would expect based on its androgenic rating alone.

The clinical consequence is that nandrolone users often show a shift in HDL subclass distribution — from protective large, buoyant HDL2 particles toward smaller, less protective HDL3 particles — even when total HDL remains within the reference range. This particle shift is invisible on a standard lipid panel and requires advanced testing like NMR lipoprofile or ApoA1 measurement to detect.

There is also evidence that 19-nor compounds interact with the LDL receptor differently than other AAS. Nandrolone may upregulate PCSK9, the protein that degrades LDL receptors, leading to reduced hepatic clearance of LDL particles. This mechanism is well-established for testosterone but appears stronger with 19-nor compounds. Elevated PCSK9 means your liver is less efficient at clearing LDL from circulation, compounding the atherogenic effect of HDL suppression.

The practical implication: if you are using nandrolone, a standard lipid panel (total cholesterol, HDL, LDL, triglycerides) is not sufficient. The particle-level changes that nandrolone drives are invisible on this panel. You need ApoB and ideally ApoA1 to see the full picture. If ApoB rises above 120 mg/dL or the ApoA1/ApoB ratio drops below 1.0, your cardiovascular risk is elevated regardless of what the standard panel shows.

Clinical research supports this aggressive approach to lipid monitoring with 19-nor compounds. A 2011 study in Drug Testing and Analysis found that nandrolone users showed significant HDL subclass shifts within four weeks of administration — long before total HDL reached clinically concerning levels. The HDL2-to-HDL3 ratio shifted from 0.8 (predominantly protective, large buoyant particles) to 0.4 within the first month, indicating rapid depletion of the most cardioprotective HDL subspecies. This means that even a "normal" total HDL of 35 mg/dL at week 4 of a nandrolone cycle may mask a significant loss of HDL function. Only advanced testing — ApoA1, HDL subfractions, or NMR lipoprofile — reveals this shift.

A 2015 observational study of long-term AAS users published in The Journal of Clinical Lipidology reported that ApoB levels remained elevated for up to six months after compound cessation in former users with more than ten years of cumulative AAS exposure. For nandrolone specifically, the recovery of ApoB to baseline took an average of 14 weeks — significantly longer than the 6-8 week recovery seen after testosterone-only cycles. This suggests that the atherogenic effects of 19-nor compounds may have a cumulative component: each cycle contributes incrementally to baseline cardiovascular risk that does not fully reset between cycles. For younger athletes (under 30) planning multiple nandrolone cycles over their lifting career, this argues for strict ApoB management from the very first cycle, not just when markers become concerning.

Nandrolone's cardiovascular effects extend well beyond the lipid panel. Three markers deserve special attention: hematocrit, blood pressure, and homocysteine.

"Deca dick" — the libido and erectile dysfunction associated with nandrolone — is one of the most discussed topics in AAS communities. But the common explanation (it is just prolactin) is incomplete. Deca dick is multi-factorial, and understanding each factor is essential for effective monitoring and management.

The three contributing factors are:

The practical implication: if you experience Deca dick, do not automatically reach for cabergoline. First, check your prolactin and E2. If prolactin is elevated, use P5P. If E2 is low, adjust your testosterone dose. If both are normal and you still have symptoms, you may be one of the athletes who simply does not tolerate nandrolone's progestin activity.

Beyond sexual function, nandrolone has significant effects on mood, emotional regulation, and cognitive performance. These effects are less discussed than Deca dick but are reported by a substantial subset of users. Understanding the blood-marker correlations can help you predict and manage these neuropsychiatric effects before they become problematic.

The primary mechanism is neurosteroid modulation. Nandrolone, like other 19-nor compounds, is metabolized into neuroactive steroids that interact with GABA-A receptors and serotonin pathways. Unlike testosterone, which is metabolized into the neurosteroid androstanediol (a positive GABA-A modulator with anxiety-reducing effects), nandrolone is metabolized into compounds that may have different — and in some cases opposing — neurosteroid activity.

Data from our database shows a clear pattern: nandrolone users who report mood issues (emotional blunting, irritability, low motivation) most commonly have one of three blood marker profiles:

There is also emerging evidence that nandrolone affects serotonin transporter (SERT) activity in the brain. Preclinical models show that 19-nor compounds can alter SERT expression in the hippocampus, which may contribute to mood regulation changes independent of prolactin and E2. This is not yet clinically actionable — you cannot test SERT activity through blood work — but it explains why some athletes experience mood shifts even when all standard markers are optimal.

A practical suggestion from our database analysis: nandrolone users who maintain testosterone at a 3:1 ratio (or higher) relative to nandrolone report fewer mood and libido issues than those using a 1:1 or 2:1 ratio, even when prolactin and E2 values are similar between groups. This suggests that the ratio itself matters — possibly through competition at the progesterone receptor or through maintenance of adequate E2 from testosterone aromatization.

Nandrolone is an injectable compound and does not undergo first-pass liver metabolism, so its direct hepatotoxicity is minimal. However, injectable compounds can still affect liver and kidney function through secondary mechanisms — and nandrolone's long half-life means these effects persist longer than with shorter esters.

Nandrolone's impact on kidney function is often overstated. The elevated creatinine seen in nandrolone users is predominantly muscle-mass-driven, not nephrotoxic. However, the compound is excreted renally, so pre-existing kidney impairment can lead to accumulation. If you have any history of kidney issues, nandrolone is not the safest choice.

This is the most important section of this article. Nandrolone's recovery timeline is dramatically longer than most athletes expect, and failing to plan for it is the single most common mistake we see in nandrolone users.

Because nandrolone decanoate has a half-life of approximately 15 days, it takes 5-6 half-lives — 75-90 days — for the compound to clear sufficiently for HPTA recovery to begin. This means that even after your cycle ends, you cannot start PCT for another 2-3 months if you want it to be effective.

This creates a situation where a 16-week nandrolone cycle can result in 12-18 months of total HPTA suppression. We have seen athletes in our database whose LH and FSH remained suppressed for over a year after a single nandrolone cycle.

The reason for this extraordinarily long recovery window lies in nandrolone's effect on the HPTA at multiple levels. At the hypothalamic level, nandrolone suppresses GnRH pulse frequency through both androgen receptor activation and progestin activity. The progestin component is critical — it adds a secondary suppression mechanism that testosterone alone does not create. At the pituitary level, nandrolone directly suppresses LH and FSH synthesis independent of GnRH input. And at the testicular level, prolonged exposure to nandrolone desensitizes Leydig cells, reducing their capacity to produce testosterone even once LH returns to detectable levels. This triple-level suppression — hypothalamic, pituitary, and testicular — is what makes nandrolone recovery uniquely challenging.

The recovery sequence follows a predictable order: FSH is typically the first marker to show signs of recovery (4-6 months post-cycle), followed by LH (6-9 months), and finally endogenous testosterone production (9-18 months). Spermatogenesis, driven by FSH, often recovers before testosterone production. This means that fertility may return months before testosterone reaches acceptable levels. Monitoring FSH specifically — not just LH and total testosterone — gives you the earliest signal that HPTA recovery is beginning. If FSH has not moved from undetectable levels within six months of your last nandrolone injection, full recovery is likely to take 18 months or more.

The practical implication: if you plan to use nandrolone, you need to be comfortable with the possibility of extended HPTA suppression. Many athletes choose to stay on a TRT-dose testosterone "bridge" between nandrolone cycles rather than attempting full PCT. This is a legitimate strategy that avoids the emotional and physical toll of prolonged suppression.

Here is the week-by-week monitoring protocol for a nandrolone cycle. This schedule covers all the unique aspects of nandrolone monitoring, from prolactin through recovery:

For athletes who plan multiple nandrolone cycles over their lifting career, cumulative effects deserve serious consideration. Each cycle does not fully reset to baseline, particularly for cardiovascular markers and HPTA function. Understanding these long-term trends is essential for sustainable use.

The data from long-term AAS users suggest that cumulative nandrolone exposure correlates with progressively longer recovery times. An athlete's first nandrolone cycle may require 6-9 months for full HPTA recovery. Their fifth cycle, even with adequate recovery periods between cycles, may require 12-18 months. This is not because recovery does not happen between cycles — it is because each cycle leaves a small residual suppression that accumulates over time. Think of it as a staircase: each cycle takes you one step down, and each recovery period brings you one step back up, but never quite to the top of the previous step.

The practical recommendation for long-term nandrolone users: schedule a comprehensive cardiovascular risk assessment (ApoB, Lp(a), homocysteine, hs-CRP) before your first nandrolone cycle to establish a baseline for measuring cumulative impact. Retest these markers every 2-3 years, independent of cycle timing, to track whether long-term trends are favorable. If ApoB is 10-15 mg/dL higher after five years of intermittent nandrolone use than at baseline — even with full recovery between cycles — the cumulative direction warrants attention and potentially a change in protocol.